Physician profile
Jeffrey T Gray
NPI 1033478748
$4,498.71
in general payments reported to CMS, 2019-2025
13 companies · $899 in 2025
The $899 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $284 · 2021: $225 · 2022: $547 · 2023: $839 · 2024: $1,244 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,982.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,827.23 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $821.20 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $570.05 | 2020-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $568.64 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $192.71 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $172.08 | 2021-2025 | |
| Allergan, INC. | $133.57 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $63.46 | 2020-2025 | Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $48.28 | 2025 | Cobenfy |
| Indivior INC. | $41.19 | 2023 | Perseris |
| Lundbeck LLC | $24.87 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $18.71 | 2023 | Qelbree |
| Janssen Scientific Affairs, LLC | $16.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.